Hereditary Paraganglioma: Evaluation of Screening Methods to Detect Tumors in SDH Positive Carriers

Pheochromocytoma Clinical Trial

Official title:

Evaluation Des méthodes de dépistage du Paragangliome héréditaire Chez Les Sujets prédisposés génétiquement

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00188019
• Other study ID #: PHRC 04-01
• Status: Completed
• Phase: N/A
• First received: September 12, 2005
• Last updated: July 22, 2015
• Start date: November 2005
• Est. completion date: November 2013

Study information

• Verified date: July 2015
• Source: University Hospital, Angers
• Contact: n/a
• Is FDA regulated: No
• Health authority: France: Ministry of Health
• Study type: Interventional

Clinical Trial Summary

Hereditary paraganglioma -due to SDH (SDHD, SDHB, SDHC) germline mutations- causes paragangliomas and pheochromocytomas. Presymptomatic genetic testing should be offered to all first-degree relatives if an SDH mutation is detected in an index case with paraganglioma or pheochromocytoma. The main objective of our national clinical research project is to test different screening methods to detect presymptomatic tumors in order to establish guidelines for the work-up and the follow-up of SDH mutation carriers.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 248
• Est. completion date: November 2013
• Est. primary completion date: November 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 6 Years and older
• Eligibility: Inclusion Criteria: identification of an SDH (SDHD, SDHD, SDHC) germline mutation

Study Design

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Related Conditions & MeSH terms

• Paraganglioma
• Pheochromocytoma

Intervention

Procedure:
• diagnosis methods

Locations

Country	Name	City	State
France	Européen Georges Pompidou Hospital	Paris

Sponsors (2)

Lead Sponsor	Collaborator
University Hospital, Angers	Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France,